Expression of Angiogenic Proteins in Tumor and Stroma Affects Survival in Patients With Gastric Cancer

Nienhüser, Henrik; Crnovrsanin, Nerma; Nerz, Daniel; Heckler, Max; Sisic, Leila; Lasitschka, Felix; Schneider, Martin; Schmidt, Thomas

doi:10.1016/j.jss.2020.05.045

Cited by 4 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical and pathological data established the role of VEGF-D in cancer, as high VEGF-D expression is linked to poor outcomes. Increased VEGF-D expression is an independent negative prognostic marker in ovarian carcinoma, colorectal cancer, breast cancer, and gastric carcinoma [145][146][147][148][149]. Furthermore, in different grades of endometrial cancer, a higher VEGF-D expression was observed in correlation to a higher tumor grade [150].…”

Section: Clinical Significance Of Vegf-d In Tumor Angiogenesismentioning

confidence: 99%

Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors

Bokhari,

Hamar

2023

IJMS

View full text Add to dashboard Cite

Vascular endothelial growth factors (VEGFs) are the key regulators of vasculogenesis in normal and oncological development. VEGF-A is the most studied angiogenic factor secreted by malignant tumor cells under hypoxic and inflammatory stress, which made VEGF-A a rational target for anticancer therapy. However, inhibition of VEGF-A by monoclonal antibody drugs led to the upregulation of VEGF-D. VEGF-D was primarily described as a lymphangiogenic factor; however, VEGF-D’s blood angiogenic potential comparable to VEGF-A has already been demonstrated in glioblastoma and colorectal carcinoma. These findings suggested a role for VEGF-D in facilitating malignant tumor growth by bypassing the anti-VEGF-A antiangiogenic therapy. Owing to its high mitogenic ability, higher affinity for VEGFR-2, and higher expression in cancer, VEGF-D might even be a stronger angiogenic driver and, hence, a better therapeutic target than VEGF-A. In this review, we summarized the angiogenic role of VEGF-D in blood vasculogenesis and its targetability as an antiangiogenic therapy in cancer.

show abstract

Section: Clinical Significance Of Vegf-d In Tumor Angiogenesismentioning

confidence: 99%

Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors

Bokhari,

Hamar

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…However, high serum angiopoietin-2 levels are associated with a poor survival outcome in patients randomized for the AVAGAST trial which again emphasizes the role of angiogenesis in esophagogastric junction tumors [ 36 , 38 ]. Further research on other angiogenesis mediating signaling pathways is needed to develop alternative or complementary approaches to pharmacologically target tumor angiogenesis in esophageal cancer [ 39 ].…”

Section: Endothelial Cells and Tumor Angiogenesismentioning

confidence: 99%

Tumor Microenvironment of Esophageal Cancer

Schiffmann

Plum

Fuchs

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Esophageal cancer is among the top ten most deadly cancers worldwide with adenocarcinomas of the esophagus showing increasing incidences over the last years. The prognosis is determined by tumor stage at diagnosis and in locally advanced stages by response to (radio-)chemotherapy followed by radical surgery. Less than a third of patients with esophageal adenocarcinomas completely respond to neoadjuvant therapies which urgently asks for further strategies to improve these rates. Aiming at the tumor microenvironment with novel targeted therapies can be one strategy to achieve this goal. This review connects experimental, translational, and clinical findings on each component of the esophageal cancer tumor microenvironment involving tumor angiogenesis, tumor-infiltrating immune cells, such as macrophages, T-cells, myeloid-derived suppressor cells, and cancer-associated fibroblasts. The review evaluates the current state of already approved concepts and depicts novel potentially targetable pathways related to esophageal cancer tumor microenvironment.

show abstract

Prognostic Relevance of the Proximal Resection Margin Distance in Distal Gastrectomy for Gastric Adenocarcinoma

Rompen,

Schütte,

Crnovrsanin

et al. 2024

Ann Surg Oncol

View full text Add to dashboard Cite

Background The risk for recurrence in patients with distal gastric cancer can be reduced by surgical radicality. However, dispute exists about the value of the proposed minimum proximal margin distance (PMD). Here, we assess the prognostic value of the safety distance between the proximal resection margin and the tumor. Patients and Methods This is a single-center cohort study of patients undergoing distal gastrectomy for gastric adenocarcinoma (2001–2021). Cohorts were defined by adequacy of the PMD according to the European Society for Medical Oncology (ESMO) guidelines (≥ 5 cm for intestinal and ≥ 8 cm for diffuse Laurén’s subtypes). Overall survival (OS) and time to progression (TTP) were assessed by log-rank and multivariable Cox-regression analyses. Results Of 176 patients, 70 (39.8%) had a sufficient PMD. An adequate PMD was associated with cancer of the intestinal subtype (67% vs. 45%, p = 0.010). Estimated 5-year survival was 63% [95% confidence interval (CI) 51–78] and 62% (95% CI 53–73) for adequate and inadequate PMD, respectively. Overall, an adequate PMD was not prognostic for OS (HR 0.81, 95% CI 0.48–1.38) in the multivariable analysis. However, in patients with diffuse subtype, an adequate PMD was associated with improved oncological outcomes (median OS not reached versus 131 months, p = 0.038, median TTP not reached versus 88.0 months, p = 0.003). Conclusion Patients with diffuse gastric cancer are at greater risk to undergo resection with an inadequate PMD, which in those patients is associated with worse oncological outcomes. For the intestinal subtype, there was no prognostic association with PMD, indicating that a distal gastrectomy with partial preservation of the gastric function may also be feasible in the setting where an extensive PMD is not achievable.

show abstract

Expression of Angiogenic Proteins in Tumor and Stroma Affects Survival in Patients With Gastric Cancer

Cited by 4 publications

References 38 publications

Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors

Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors

Tumor Microenvironment of Esophageal Cancer

Prognostic Relevance of the Proximal Resection Margin Distance in Distal Gastrectomy for Gastric Adenocarcinoma

Contact Info

Product

Resources

About